Methotrexate and cardiovascular prevention: an appraisal of the current evidence
Therapeutic Advances in Cardiovascular Disease · 2023-01 · 17
DOI: 10.1177/17539447231215213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 20.12.2023. Verfasst von Arduino A Mangoni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cardiovascular System, Methotrexate, Rheumatic Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
New evidence continues to accumulate regarding a significant association between excessive inflammation and dysregulated immunity (local and systemic) and the risk of cardiovascular events in different patient cohorts. Whilst research has sought to identify novel atheroprotective therapies targeting inflammation and immunity, several marketed drugs for rheumatological conditions may serve a similar purpose. One such drug, methotrexate, has been used since 1948 for treating cancer and, more recently, for a wide range of dysimmune conditions. Over the last 30 years, epidemiological and experimental studies have shown that methotrexate is independently associated with a reduced risk of cardiovascular disease, particularly in rheumatological patients, and exerts several beneficial effects on vascular homeostasis and blood pressure control. This review article discusses the current challenges with managing cardiovascular risk and the new frontiers offered by drug discovery and drug repurposing targeting inflammation and immunity with a focus on methotrexate. Specifically, the article critically appraises the results of observational, cross-sectional and intervention studies investigating the effects of methotrexate on overall cardiovascular risk and individual risk factors. It also discusses the putative molecular mechanisms underpinning the atheroprotective effects of methotrexate and the practical advantages of using methotrexate in cardiovascular prevention, and highlights future research directions in this area.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia.
- Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, SA 5042, Australia.
- Department of Biomedical Sciences, University of Sassari, Sassari, Italy; Quality Control Unit, University Hospital (AOUSS), Sassari, Italy.
- Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
- Quality Control Unit, University Hospital (AOUSS), Sassari, Italy.
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
ORCID-Profile: Arduino A Mangoni
Zitieren
APA
Mangoni, A. A., Sotgia, S., Zinellu, A., Carru, C., Pintus, G., Damiani, G., Erre, G. L., & Tommasi, S. (2023). Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Therapeutic Advances in Cardiovascular Disease, 17. https://doi.org/10.1177/17539447231215213
Vancouver
Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, et al. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Therapeutic Advances in Cardiovascular Disease. 2023;17. doi:10.1177/17539447231215213
BibTeX
@article{Mangoni2023,
author = {Mangoni, Arduino A and Sotgia, Salvatore and Zinellu, Angelo and Carru, Ciriaco and Pintus, Gianfranco and Damiani, Giovanni and Erre, Gian Luca and Tommasi, Sara},
title = {Methotrexate and cardiovascular prevention: an appraisal of the current evidence},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2023},
volume = {17},
doi = {10.1177/17539447231215213}
}
EUVIMED